The nutritional supplements company on Monday unveiled a deal to sell to private equity firm HGGC in a transaction valued at about $446M, including debt to be refinanced.
Davids that follow Amazon's example may ultimately beat Goliath to the punch.
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
Here's a tech name that's becoming more shareholder friendly.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.